Migraine is more than just a headache. It is a chronic, often disabling neurological disease and a significant source of lost productivity, reduced quality of life, and rising medical costs, especially within the federal health system. The objective of the session is to provide participants with practical insights into integrating migraine treatment within federal medicine, with the goal of impacting migraine care and improving patient outcomes. Attendees will gain an understanding of how targeted therapies can provide hope for people living with migraine who have previously faced limited treatment options and frequent debilitating attacks. This program will explore the substantial burden of migraine among individuals served by federal medicine, highlighting the unmet needs in this population. The session will focus on: 1. The evolution of migraine treatment landscape from the use of traditional, non-migraine specific medications to targeted therapies that are part of today’s approach to migraine management. 2. A focused review of Phase 3 clinical data supporting Abbvie's migraine treatments. 3. Recent real-world data highlighting patient-centered outcomes for Abbvie products.